Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

Core Insights - Immix Biopharma is on track for the first FDA Biologics License Application (BLA) approved cell therapy for relapsed/refractory AL Amyloidosis, having surpassed the 50% enrollment milestone in the NEXICART-2 clinical trial [1][2] Company Overview - Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for AL Amyloidosis and other serious diseases [5] - The lead candidate, NXC-201, is a sterically-optimized BCMA-targeted CAR-T cell therapy designed to filter out non-specific activation [4][5] - NXC-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug Designation (ODD) from the FDA and EMA [4][5] Clinical Trial Details - NEXICART-2 (NCT06097832) is a multi-site Phase 1/2 clinical trial for NXC-201 in relapsed/refractory AL Amyloidosis, expected to enroll 40 patients [3] - Interim results from NEXICART-2 were presented at ASCO 2025, indicating positive progress towards BLA submission [2][5] Market Insights - The U.S. prevalence of relapsed/refractory AL Amyloidosis is projected to grow at 12% annually, reaching approximately 37,270 patients by 2025 [6] - The amyloidosis market was valued at $3.6 billion in 2017 and is expected to reach $6 billion by 2025 [7]